英夫利昔单抗治疗炎症性肠病的研究进展

肿瘤坏死因子－α（TNF－α）是一种促炎细胞因子，在炎症性肠病（IBD）的发病过程中起重要作用。英夫利昔，单抗（infliximab）是一种人-鼠嵌合型TNF-αIgGl单克隆抗体，与体内多种形式的TNF-α有较强结合能力。美国食品药品管理局（FDA）于1998年批准该制剂用于治疗传统药物治疗无效的中重度或合并瘘管的克罗恩病（CD），试验显示其对难治性活动性溃疡性结肠炎（UC）亦有一定疗效。英夫利昔单抗的使用已积累了10年的经验，本文对其作用机制、疗效、安全性方面的研究进展作一综述。

Infliximab Therapy in Inflammatory Bowel Disease

Tumor necrosis factor-α （TNF-α） is a proinflammatory cytokine that plays a crucial role in the pathogenesis of inflammatory bowel disease （IBD）. Infliximab is a chimeric mouse-human monoclonal IgG1 antibody with high affinity for soluble and membrane forms of TNF-α. The Food and Drug Administration （FDA） approved infliximab in 1998 for use in moderate to severe or fistulizing Crohn＇s disease （CD） refractory to conventional therapies, likewise, it has been shown that infliximab is also effective in treating active ulcerative colitis （UC） resistant to standard medical therapy. Based on a decade of experiences, this article is aimed to review the mechanism of action, efficacy and safety of infliximab in the treatment of IBD.